SUBSCRIBE
SUBSCRIBE
News   Drug Development

Introgen Therapeutics, Inc.'s Flagship Cancer Drug Advexin Questioned

July 15, 2008 | 
1 min read
Introgen Therapeutics Inc. saw its stock price plummet about 20 percent Monday, the same day a report from TheStreet.com was published questioning the effectiveness of the company's much-touted cancer drug Advexin.
Clinical research Phase 1 Phase 2
MORE ON THIS TOPIC
Dream Birds Flying Away, the birds flying out of a bird an open cage, the birds released from a cage, freedom concept. birds set free vector illustration.
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie
Pulsing heart collage illustration, sign of life. Isolated human heart organ with glowing red line surrounding, black and white
Rare disease
Aardvark Tanks After Pausing Prader-Willi Study on ‘Surprise’ Safety Signals
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Halftone hand holding pen or stylus and writing on torn paper piece art collage banner template with copy space for text. Cut out shapes, hand gesture. Grunge modern retro vector illustration
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac